Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Wake Forest University |
---|---|
Information provided by: | Wake Forest University |
ClinicalTrials.gov Identifier: | NCT00658112 |
The purpose of this research study is to see how often benzoyl peroxide is applied for acne. Use of medication was monitored electronically.
Condition | Intervention | Phase |
---|---|---|
Acne Vulgaris |
Drug: Benzoyl Peroxide |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment |
Official Title: | Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne |
Enrollment: | 20 |
Study Start Date: | July 2006 |
Study Completion Date: | May 2008 |
Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Benzoyl Peroxide 5%
|
Drug: Benzoyl Peroxide
Benzoyl peroxide 5% gel. Applied once daily to face, minimum amount usable to cover area. Every day for six weeks.
|
We give subjects topical benzoyl peroxide, a standard first line acne treatment, in a container that records when the container is opened and closed.
Subjects will simply be asked to "return in six weeks to see how well benzoyl peroxide works for them." Subjects initially will not be told that they are participating in a formal study. When they return with their medication, we will seek their informed consent to participate in the study.
Verbal consent will be obtained at the beginning of the study. There will be no written consent obtained until the end of the study. By doing this, subjects will not be aware that adherence is being measured. Subjects will not be aware that they are participating in a study. Only if they consent would we then collect the medication container and monitor and retrieve the adherence data. If they do not consent, we will not have collected any research data on them except baseline acne severity measures which may have been collected anyway as part of their clinic treatment.
Ages Eligible for Study: | 13 Years to 18 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, North Carolina | |
Wake Forest University Health Sciences Dermatology | |
Winston Salem, North Carolina, United States, 27157 |
Principal Investigator: | Steven R Feldman, MD | Wake Forest University |
Responsible Party: | Wake Forest University Health Sciences ( Steve Feldman, MD ) |
Study ID Numbers: | 0000027 |
Study First Received: | April 9, 2008 |
Last Updated: | June 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00658112 History of Changes |
Health Authority: | United States: Institutional Review Board |
Exanthema Facial Dermatoses Facies Skin Diseases |
Benzoyl Peroxide Sebaceous Gland Diseases Acne Vulgaris |
Facial Dermatoses Skin Diseases Acneiform Eruptions Therapeutic Uses Benzoyl Peroxide |
Sebaceous Gland Diseases Dermatologic Agents Pharmacologic Actions Acne Vulgaris |